Crinetics Announces July 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces July 2023 inducement grants: the stock options were granted as inducements material to 10 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023


Data from the Crinetics Phase 2 Advance study of oral paltusotine was presented at ENDO 2023, along with proof-of-concept data from programs for primary hyperparathyroidism and thyroid eye disease

Crinetics Announces June 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces June 2023 inducement grants: the stock options were granted as inducements material to 14 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics to Highlight Broad Pipeline at ENDO 2023


Crinetics Pharmaceuticals highlighting broad pipeline at ENDO 2023 with oral and poster presentations on several programs, including candidates for primary hyperparathyroidism and thyroid eye disease

Crinetics Announces May 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces May 2023 inducement grants: the stock options were granted as inducements material to nine employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).